WALTHAM, Mass., Feb. 27 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Alternext US: ILI) announced today that it will host a conference call and Webcast on Monday, March 9, 2009, at 4:30 p.m. EDT to review the Company's fourth quarter and year end 2008 financial results, and provide an update on recent corporate developments.
To access the live call, dial 877-795-3646 (domestic) or 719-325-4833 (international). The live Webcast and replay access of the teleconference will be available on the Investors section of the Company's Website at http://www.ilgenetics.com.
Interleukin Genetics, Inc. (NYSE Alternext US: ILI), is a healthcare company that specializes in the development of genetic biomarker tests for sale to the emerging personalized health market. The Company is focused on the future of health and medicine. Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and commercialize innovative diagnostic and risk assessment genetic tests. These products could help to improve an individual's understanding of needed lifestyle changes or of therapeutic products that can be used to better manage their health. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. Through its AJG subsidiary, the Company also currently offers an array of Nutraceutical and OTCeuticals(R) products, including Ginkoba(TM), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics and its ongoing programs, please visit www.ilgenetics.com.
|SOURCE Interleukin Genetics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved